RBC is OFF on its Pg revenueRBC projected $14M revenue from t he sale of Pg based on approval of this trial in H1 of 2017. What they are missing is that there is a huge market for Pg for the wound healing indication. I know, the approval for that will be further down the road but has been largely derisked. Here comes the point RBC missed. Once PLI's Pg is on the market commercially doctors can prescribe it OFF-LABEL even before it is approved for that indication. So if say only 5% od the wound healing is done in this fashion prior to FDA approval that itself is a huge market potential as soon as this indication for Pg goes commercial in nid 2017!
So this will bring in way more than the mere $14M that RBC mentions. FD, can you confirm this thought and perhaps firm it up with some numbers?